Afatinib for the treatment of advanced non-small-cell lung cancer

Carlo Genova, Erika Rijavec, Giulia Barletta, Giovanni Burrafato, Federica Biello, Maria Giovanna Dal Bello, Simona Coco, Anna Truini, Angela Alama, Francesco Boccardo, Francesco Grossi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction: The inhibition of the epidermal growth factor receptor (EGFR) through tyrosine kinase inhibitors (TKIs) represents an effective strategy for EGFR-mutated NSCLC. Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients. Areas covered: The authors analyzed the pharmacology and the clinical activity of afatinib in NSCLC through a review of the literature. Trials exploring different settings have been reported, including LUX-Lung 3 and LUX-Lung 6, where the drug achieved better outcomes in terms of response rate, progression-free survival and quality of life compared with chemotherapy. The main toxicities of afatinib are gastrointestinal and skin-related adverse events. Expert opinion: Afatinib showed remarkable efficacy as a first-line treatment in the presence of common EGFR mutations. Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. Direct clinical data comparing the activity and tolerability of different inhibitors are still needed.

Original languageEnglish
Pages (from-to)889-903
Number of pages15
JournalExpert Opinion on Pharmacotherapy
Volume15
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Therapeutics
Lung
Clinical Pharmacology
Expert Testimony
BIBW 2992
Oncogenes
Disease-Free Survival
Japan
Quality of Life
Drug Therapy
Skin
Mutation
Pharmaceutical Preparations

Keywords

  • Afatinib
  • EGFR mutation
  • Irreversible EGFR inhibitors
  • NSCLC
  • Pan HER inhibitor

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Genova, C., Rijavec, E., Barletta, G., Burrafato, G., Biello, F., Dal Bello, M. G., ... Grossi, F. (2014). Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opinion on Pharmacotherapy, 15(6), 889-903. https://doi.org/10.1517/14656566.2014.902445

Afatinib for the treatment of advanced non-small-cell lung cancer. / Genova, Carlo; Rijavec, Erika; Barletta, Giulia; Burrafato, Giovanni; Biello, Federica; Dal Bello, Maria Giovanna; Coco, Simona; Truini, Anna; Alama, Angela; Boccardo, Francesco; Grossi, Francesco.

In: Expert Opinion on Pharmacotherapy, Vol. 15, No. 6, 2014, p. 889-903.

Research output: Contribution to journalArticle

Genova, C, Rijavec, E, Barletta, G, Burrafato, G, Biello, F, Dal Bello, MG, Coco, S, Truini, A, Alama, A, Boccardo, F & Grossi, F 2014, 'Afatinib for the treatment of advanced non-small-cell lung cancer', Expert Opinion on Pharmacotherapy, vol. 15, no. 6, pp. 889-903. https://doi.org/10.1517/14656566.2014.902445
Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG et al. Afatinib for the treatment of advanced non-small-cell lung cancer. Expert Opinion on Pharmacotherapy. 2014;15(6):889-903. https://doi.org/10.1517/14656566.2014.902445
Genova, Carlo ; Rijavec, Erika ; Barletta, Giulia ; Burrafato, Giovanni ; Biello, Federica ; Dal Bello, Maria Giovanna ; Coco, Simona ; Truini, Anna ; Alama, Angela ; Boccardo, Francesco ; Grossi, Francesco. / Afatinib for the treatment of advanced non-small-cell lung cancer. In: Expert Opinion on Pharmacotherapy. 2014 ; Vol. 15, No. 6. pp. 889-903.
@article{05ec8974827f418e9ac7ec35eb998be8,
title = "Afatinib for the treatment of advanced non-small-cell lung cancer",
abstract = "Introduction: The inhibition of the epidermal growth factor receptor (EGFR) through tyrosine kinase inhibitors (TKIs) represents an effective strategy for EGFR-mutated NSCLC. Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients. Areas covered: The authors analyzed the pharmacology and the clinical activity of afatinib in NSCLC through a review of the literature. Trials exploring different settings have been reported, including LUX-Lung 3 and LUX-Lung 6, where the drug achieved better outcomes in terms of response rate, progression-free survival and quality of life compared with chemotherapy. The main toxicities of afatinib are gastrointestinal and skin-related adverse events. Expert opinion: Afatinib showed remarkable efficacy as a first-line treatment in the presence of common EGFR mutations. Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. Direct clinical data comparing the activity and tolerability of different inhibitors are still needed.",
keywords = "Afatinib, EGFR mutation, Irreversible EGFR inhibitors, NSCLC, Pan HER inhibitor",
author = "Carlo Genova and Erika Rijavec and Giulia Barletta and Giovanni Burrafato and Federica Biello and {Dal Bello}, {Maria Giovanna} and Simona Coco and Anna Truini and Angela Alama and Francesco Boccardo and Francesco Grossi",
year = "2014",
doi = "10.1517/14656566.2014.902445",
language = "English",
volume = "15",
pages = "889--903",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Afatinib for the treatment of advanced non-small-cell lung cancer

AU - Genova, Carlo

AU - Rijavec, Erika

AU - Barletta, Giulia

AU - Burrafato, Giovanni

AU - Biello, Federica

AU - Dal Bello, Maria Giovanna

AU - Coco, Simona

AU - Truini, Anna

AU - Alama, Angela

AU - Boccardo, Francesco

AU - Grossi, Francesco

PY - 2014

Y1 - 2014

N2 - Introduction: The inhibition of the epidermal growth factor receptor (EGFR) through tyrosine kinase inhibitors (TKIs) represents an effective strategy for EGFR-mutated NSCLC. Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients. Areas covered: The authors analyzed the pharmacology and the clinical activity of afatinib in NSCLC through a review of the literature. Trials exploring different settings have been reported, including LUX-Lung 3 and LUX-Lung 6, where the drug achieved better outcomes in terms of response rate, progression-free survival and quality of life compared with chemotherapy. The main toxicities of afatinib are gastrointestinal and skin-related adverse events. Expert opinion: Afatinib showed remarkable efficacy as a first-line treatment in the presence of common EGFR mutations. Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. Direct clinical data comparing the activity and tolerability of different inhibitors are still needed.

AB - Introduction: The inhibition of the epidermal growth factor receptor (EGFR) through tyrosine kinase inhibitors (TKIs) represents an effective strategy for EGFR-mutated NSCLC. Afatinib is an irreversible erythroblastosis oncogene B (ErbB) family blocker, able to inhibit the kinase domains of EGFR, HER2 and HER4, and the transphosphorylation of ErbB3 that has recently been approved in the United States for the first-line treatment of EGFR-mutated NSCLC and in Europe and Japan for the treatment of EGFR-mutated TKI-naive patients. Areas covered: The authors analyzed the pharmacology and the clinical activity of afatinib in NSCLC through a review of the literature. Trials exploring different settings have been reported, including LUX-Lung 3 and LUX-Lung 6, where the drug achieved better outcomes in terms of response rate, progression-free survival and quality of life compared with chemotherapy. The main toxicities of afatinib are gastrointestinal and skin-related adverse events. Expert opinion: Afatinib showed remarkable efficacy as a first-line treatment in the presence of common EGFR mutations. Afatinib showed some activity in NSCLC with acquired resistance to EGFR TKIs, although, currently, its efficacy after the failure of erlotinib or gefitinib has not been clearly stated. Direct clinical data comparing the activity and tolerability of different inhibitors are still needed.

KW - Afatinib

KW - EGFR mutation

KW - Irreversible EGFR inhibitors

KW - NSCLC

KW - Pan HER inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84896466565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896466565&partnerID=8YFLogxK

U2 - 10.1517/14656566.2014.902445

DO - 10.1517/14656566.2014.902445

M3 - Article

C2 - 24646054

AN - SCOPUS:84896466565

VL - 15

SP - 889

EP - 903

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 6

ER -